Top

Published in:

Open Access 01-03-2017 | Therapy in Practice

Clinical Effects of Topiroxostat on Renal and Endothelial Function in A Patient with Chronic Kidney Disease and Hyperuricemic Arteriolopathy: A Case Report

Authors: Atsushi Tanaka, Tsukasa Nakamura, Eiichi Sato, Koichi Node

Published in: Drugs in R&D | Issue 1/2017

Abstract

Hyperuricemia is associated with the progression of chronic kidney disease (CKD) and cardiovascular diseases. Topiroxostat, a selective xanthine oxidase inhibitor, effectively reduces serum uric acid (UA) levels and urinary albumin excretion (UAE) in CKD patients. A 50-year-old Japanese man was referred to our hospital due to albuminuria and hyperuricemia, and renal biopsy showed a typical hyperuricemic arteriolopathy. Treatment with topiroxostat decreased serum UA levels (9.2 mg/dL at baseline to 6.4 mg/dL after 6 months), UAE (388 to 88 mg/g.cr), and urinary level of liver-type fatty acid-binding protein (28.8 to 19.8 µg/g.cr). Interestingly, topiroxostat treatment was associated with a trend towards improved flow-mediated dilation (5.4 to 5.8%). These results suggested that topiroxostat in CKD patients with hyperuricemia is potentially effective, not only for ameliorating renal damages but also for improving endothelial function beyond its UA-lowering action.

Xia X, Luo Q, Li B, Lin Z, Yu X, Husng F. Serum uric acid and mortality in chronic kidney disease: a systemic review and meta-analysis. Metabolism. 2016;65:1326–41.CrossRefPubMed

Takae K, Nagata M, Hata J, Mukai N, Hirakawa Y, Yoshida D, et al. Serum uric acid as a risk factor for chronic kidney disease in a Japanese community: the Hisayama Study. Circ J. 2016;80:1857–62.CrossRefPubMed

Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazza M, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13:2888–97.CrossRefPubMed

Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282:F991–7.CrossRefPubMed

Kohagura K, Koichi M, Miyagi T, Kinjo T, Maehara Y, Nagahama K, et al. An association between uric acid levels and renal arteriopathy in chronic kidney disease: a biopsy-based study. Hypertens Res. 2013;36:43–9.CrossRefPubMed

Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51–9.CrossRefPubMed

Nakamura T, Murase T, Nampei M, Morimoto N, Ashizawa N, Iwanaga T, et al. Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice. Eur J Pharmacol. 2016;780:224–31.CrossRefPubMed

Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, et al. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clin Exp Nephrol. 2014;18:876–84.CrossRefPubMedPubMedCentral

Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57:109–15.CrossRefPubMed

10.

Wang J, Qin T, Chen J, Li Y, Wang L, Huang H, et al. Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies. PLoS One. 2014;9:e114259.CrossRefPubMedPubMedCentral

11.

Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015;33:1729–41.CrossRefPubMed

12.

Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol. 2014;15:122.CrossRefPubMedPubMedCentral

13.

Uchida S, Chang WX, Ota T, Tamura Y, Shiraishi T, Kumagai T, et al. Targeting uric acid and the inhibition of progression to end-stage renal disease: a propensity score analysis. PLoS One. 2015;10:e0145506.CrossRefPubMedPubMedCentral

14.

Sánchez-Lozada LG, Tapia E, Avila-Casado C, Soto V, Franco M, Santamaría J, et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol. 2002;283:F1105–10.CrossRefPubMed

15.

Bose B, Badve SV, Hiremath SS, Boudville N, Brown FG, Cass A, et al. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2014;29:406–13.CrossRefPubMed

16.

Matsumoto K, Okamoto K, Ashizawa N, Nishino T. FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase. J Pharmacol Exp Ther. 2011;336:95–103.CrossRefPubMed

17.

Kamijo-Ikemori A, Sugaya T, Hibi C, Nakamura T, Murase T, Oikawa T, et al. Renoprotective effect of the xanthine oxidoreductase inhibitor topiroxostat on adenine-induced renal injury. Am J Physiol Renal Physiol. 2016;310:F1366–76.CrossRefPubMed

18.

Matsui K, Kamijo-Ikemori A, Imai N, Sugaya T, Yasuda T, Tatsunami S, et al. Clinical significance of urinary liver-type fatty acid-binding protein as a predictor of ESRD and CVD in patients with CKD. Clin Exp Nephrol. 2016;20:195–203.CrossRefPubMed

19.

Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67:1739–42.CrossRefPubMed

20.

Chen J, Hamm LL, Mohler ER, Hudaihed A, Arora R, Chen CS, et al. Interrelationship of multiple endothelial dysfunction biomarkers with chronic kidney disease. PLoS One. 2015;10:e0132047.CrossRefPubMedPubMedCentral

21.

Bayram D, Tuğrul Sezer M, İnal S, Altuntaş A, Kıdır V, Orhan H. The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients. Clin Exp Nephrol. 2015;19:443–9.CrossRefPubMed

22.

Jalal DI, Decker E, Prrenoud L, Nowak KL, Bispham N, Mehta T, et al. Vascular function and uric acid-lowering in stage 3 CKD. J Am Soc Nephrol (Epub 12 Sep 2016). pii: ASN.2016050521.

23.

Sezai A, Soma M, Nakata K, Hata M, Yoshitake I, Wakui S, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial). Circ J. 2013;77:2043–9.CrossRefPubMed

24.

Sezai A, Soma M, Nakata K, Osaka S, Ishii Y, Yaoita H, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD). J Cardiol. 2015;66:298–303.CrossRefPubMed

25.

Oyama J, Tanaka A, Sato Y, Tomiyama H, Sata M, Ishizu T, et al. PRIZE Study Investigators. Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study. Cardiovasc Diabetol. 2016;15:87.CrossRefPubMedPubMedCentral

26.

Kato S, Ando M, Mizukoshi T, Nagata T, Katsuno T, Kosugi T, et al. Randomized control trial for the assessment of the anti-albuminuric effects of topiroxostat in hyperuricemic patients with diabetic nephropathy (the ETUDE study). Nagoya J Med Sci. 2016;78:135–42.PubMedPubMedCentral

Title: Clinical Effects of Topiroxostat on Renal and Endothelial Function in A Patient with Chronic Kidney Disease and Hyperuricemic Arteriolopathy: A Case Report
Authors: Atsushi Tanaka
Tsukasa Nakamura
Eiichi Sato
Koichi Node
Publication date: 01-03-2017
Publisher: Springer International Publishing
Published in: Drugs in R&D / Issue 1/2017
Print ISSN: 1174-5886
Electronic ISSN: 1179-6901
DOI: https://doi.org/10.1007/s40268-016-0169-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Clinical Effects of Topiroxostat on Renal and Endothelial Function in A Patient with Chronic Kidney Disease and Hyperuricemic Arteriolopathy: A Case Report

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI

A Review of Clinical Outcomes Associated with Two Meropenem Dosing Strategies

Safety Profile Based on Concordance of Nonclinical Toxicity and Clinical Adverse Drug Reactions for Blood Cancer Drugs Approved in Japan

Population Pharmacokinetics and Pharmacodynamics Modelling of Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome

Antithyroid Drug-Induced Agranulocytosis: State of the Art on Diagnosis and Management

Identification of a Syndrome Class of Neuropsychiatric Adverse Reactions to Mefloquine from Latent Class Modeling of FDA Adverse Event Reporting System Data